Германия - немецкий - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

biologische heilmittel heel gmbh (3061574) - acidum nitricum (pot.-angaben); conyza canadensis (pot.-angaben); viburnum opulus (pot.-angaben); pulsatilla pratensis (pot.-angaben); cyclamen purpurascens (pot.-angaben); strychnos ignatii (pot.-angaben); aquilegia vulgaris (pot.-angaben); origanum majorana (pot.-angaben); myristica fragrans (pot.-angaben); sepia officinalis (pot.-angaben); calcium carbonicum hahnemanni (pot.-angaben) - flüssige verdünnung zur injektion - acidum nitricum (pot.-angaben) (02123) 2,5 milligramm; conyza canadensis (pot.-angaben) (06142) 2,5 milligramm; viburnum opulus (pot.-angaben) (02184) 2,5 milligramm; pulsatilla pratensis (pot.-angaben) (01991) 2,5 milligramm; cyclamen purpurascens (pot.-angaben) (06194) 2,5 milligramm; strychnos ignatii (pot.-angaben) (02478) 2,5 milligramm; aquilegia vulgaris (pot.-angaben) (14175) 5 milligramm; origanum majorana (pot.-angaben) (14999) 5 milligramm; myristica fragrans (pot.-angaben) (05309) 5 milligramm; sepia officinalis (pot.-angaben) (02189) 250 milligramm; calcium carbonicum hahnemanni (pot.-angaben) (02195) 5 milligramm - kaninchen; pferd; ziege; hund; schaf; ziervogel; katze; rind; nagetiere, kleine; schwein

Германия - немецкий - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

hanosan gmbh (3078439) - gelsemium sempervirens (pot.-angaben); coffea arabica (pot.-angaben); pulsatilla pratensis (pot.-angaben); atropa bella-donna (pot.-angaben); cyclamen purpurascens (pot.-angaben) - tablette - teil 1 - tablette; gelsemium sempervirens (pot.-angaben) (01273) 60 milligramm; coffea arabica (pot.-angaben) (03731) 3 milligramm; pulsatilla pratensis (pot.-angaben) (01991) 0,3 milligramm; atropa bella-donna (pot.-angaben) (20609) 30 milligramm; cyclamen purpurascens (pot.-angaben) (06194) 6 milligramm

Германия - немецкий - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

staufen-pharma gmbh & co.kg - gangränöse-pulpa-nosode (pot.-angaben) - flüssige verdünnung zur injektion - gangränöse-pulpa-nosode (pot.-angaben) 1.1ml

Австрия - немецкий - AGES (Agentur für Gesundheit und Ernährungssicherheit)

biologische heilmittel heel gmbh - acidum nitricum (hab); aquilegia vulgaris (hab); calcium carbonicum hahnemanni (hab); capsella bursa-pastoris (hab); conyza canadensis (hab); cyclamen purpurascens (hab); cypripedium parviflorum var. pubescens (hab); moschus moschiferus (komm d); myristica fragrans (hab); origanum majorana (hab); pulsatilla pratensis (hab); senecio nemorensis (komm d); sepia officinalis (hab); strychnos ignatii (hab); viburnum opulus (hab) -

Австрия - немецкий - AGES (Agentur für Gesundheit und Ernährungssicherheit)

biologische heilmittel heel gmbh - moschus moschiferus (komm d); cyclamen purpurascens (hab); calcium carbonicum hahnemanni (hab); capsella bursa-pastoris (hab); salpetersÄure; sepia; strychnos ignatii (hab); herba pulsatillae cum radice (auszug); viburnum opulus (hab); senecio ex herba (hom); cypripedium parviflorum var. pubescens (hab); conyza canadensis (hab); aquilegia vulgaris (hab); origanum majorana (hab); myristicae semen (auszug) -

Австрия - немецкий - AGES (Agentur für Gesundheit und Ernährungssicherheit)

restaxil gmbh - cimicifuga racemosa (hab); cyclamen purpurascens (hab); gelsemium sempervirens (hab); iris versicolor (hab); spigelia anthelmia (hab) -

Европейский союз - немецкий - EMA (European Medicines Agency)

samsung bioepis nl b.v. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; hidradenitis suppurativa; arthritis - immunsuppressiva - rheumatoide arthritisimraldi in kombination mit methotrexat ist indiziert zur:behandlung der mittelschweren bis schweren, aktiven rheumatoiden arthritis bei erwachsenen patienten, wenn die response an disease-modifying anti-rheumatic drugs inklusive methotrexat ungeeignet gewesen. die behandlung der schweren, aktiven und progressiven rheumatoiden arthritis bei erwachsenen, die zuvor nicht mit methotrexat behandelt. imraldi gegeben werden kann als monotherapie im falle einer unverträglichkeit gegenüber methotrexat oder wenn die fortsetzung der behandlung mit methotrexat ungeeignet ist,. adalimumab wurde gezeigt, zur verringerung der rate des fortschreitens von gelenkschäden, wie gemessen, durch die x-ray und für die verbesserung der physischen funktion, wenn sie in kombination mit methotrexat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisimraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab wurde nicht untersucht bei patienten im alter von weniger als 2 jahren. enthesitis-related arthritisimraldi is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asimraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriasis-arthritisimraldi ist indiziert zur behandlung der aktiven und progressiven psoriasis-arthritis bei erwachsenen, wenn die reaktion auf die bisherigen disease-modifying anti-rheumatic drug-therapie nicht ausreicht,. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5. 1) und auf die verbesserung der physischen funktion. psoriasisimraldi ist indiziert für die behandlung von mittelschwerer bis schwerer chronischer plaque-psoriasis bei erwachsenen patienten, die kandidaten für eine systemische therapie. pädiatrischen plaque-psoriasisimraldi ist indiziert für die behandlung von schweren chronischen plaque-psoriasis bei kindern und jugendlichen ab 4 jahren, die haben, die unzureichend oder unangemessen sind kandidaten für eine topische therapie und lichttherapie. hidradenitis suppurativa (hs)imraldi is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 und 5. morbus crohn diseaseimraldi ist indiziert für die behandlung von mäßig bis schwer aktiver morbus crohn bei erwachsenen patienten, die nicht geantwortet haben, trotz einer vollständigen und adäquaten therapie mit einem kortikosteroid und/oder einem immunsuppressivum; oder die intolerant sind oder medizinische kontraindikationen für solche therapien. paediatric crohn's diseaseimraldi is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or haveulcerative colitisimraldi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisimraldi is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisimraldi is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whomcorticosteroid treatment is inappropriate. paediatric uveitisimraldi is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Австрия - немецкий - AGES (Agentur für Gesundheit und Ernährungssicherheit)

restaxil gmbh - cimicifuga racemosa (hab); cyclamen purpurascens (hab); gelsemium sempervirens (hab); iris versicolor (hab); spigelia anthelmia (hab) -

Европейский союз - немецкий - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; psoriasis; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; crohn disease; arthritis, juvenile rheumatoid - immunsuppressiva - rheumatoid arthritisyuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab wurde gezeigt, zur verringerung der rate des fortschreitens von gelenkschäden, wie gemessen, durch die x-ray und für die verbesserung der physischen funktion, wenn sie in kombination mit methotrexat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisyuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab wurde nicht untersucht bei patienten im alter von weniger als 2 jahren. enthesitis-related arthritisyuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asyuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriatic arthritisyuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab wurde gezeigt, zur verringerung der rate des fortschreitens peripherer gelenkschäden, wie gemessen, durch die x-ray bei patienten mit polyarticular symmetrischen subtypen der erkrankung (siehe abschnitt 5. 1) und auf die verbesserung der physischen funktion. psoriasisyuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasisyuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 und 5. crohn’s diseaseyuflyma is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaseyuflyma is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitisyuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisyuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisyuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitisyuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Германия - немецкий - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

biologische heilmittel heel gmbh (3061574) - acidum nitricum (pot.-angaben); aquilegia vulgaris (pot.-angaben); capsella bursa-pastoris (pot.-angaben); conyza canadensis (pot.-angaben); cyclamen purpurascens (pot.-angaben); cypripedium parviflorum var. pubescens (pot.-angaben); myristica fragrans (pot.-angaben); origanum majorana (pot.-angaben); pulsatilla pratensis (pot.-angaben); senecio nemorensis (pot.-angaben); strychnos ignatii (pot.-angaben); viburnum opulus (pot.-angaben); calcium carbonicum hahnemanni (pot.-angaben); sepia officinalis (pot.-a - flüssige verdünnung zur injektion - acidum nitricum (pot.-angaben) (02123) 2,5 milligramm; aquilegia vulgaris (pot.-angaben) (14175) 5 milligramm; capsella bursa-pastoris (pot.-angaben) (05801) 5 milligramm; conyza canadensis (pot.-angaben) (06142) 5 milligramm; cyclamen purpurascens (pot.-angaben) (06194) 2,5 milligramm; cypripedium parviflorum var. pubescens (pot.-angaben) (13909) 5 milligramm; myristica fragrans (pot.-angaben) (05309) 5 milligramm; origanum majorana (pot.-angaben) (14999) 5 milligramm; pulsatilla pratensis (pot.-angaben) (01991) 2,5 milligramm; senecio nemorensis (pot.-angaben) (06141) 5 milligramm; strychnos ignatii (pot.-angaben) (02478) 2,5 milligramm; viburnum opulus (pot.-angaben) (02184) 5 milligramm; calcium carbonicum hahnemanni (pot.-angaben) (02195) 5 milligramm; sepia officinalis (pot.-angaben) (02189) 250 milligramm - schwein; ziervogel; kaninchen, nicht zur lebensmittelproduktion; schaf; hund; nagetiere, kleine; katze; ziege; pferd; rind